Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

10.84 +0.65 (+6.33%)
Streaming Delayed Price Updated: 10:35 AM EDT, Jun 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 574,449
Open 10.22
Bid (Size) 10.82 (100)
Ask (Size) 10.85 (100)
Prev. Close 10.19
Today's Range 10.19 - 10.89
52wk Range 1.500 - 13.24
Shares Outstanding 46,772,263
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
Via InvestorPlace
News headline image
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Replimune, Inc.
Via GlobeNewswire

Performance

YTD
+21.7%
+21.7%
1 Month
+120.7%
+120.7%
3 Month
+55.2%
+55.2%
6 Month
+9.1%
+9.1%
1 Year
+17.4%
+17.4%

More News

Read More
News headline image
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
Top stock movements in today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Top movers in Friday's pre-market session ↗
Via Chartmill
News headline image
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
From Replimune, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Which stocks are moving before the opening bell on Monday? ↗
Via Chartmill
News headline image
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune to Present at Two Upcoming Investor Conferences
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Replimune, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
Via Chartmill

Frequently Asked Questions

Is Replimune Group, Inc. - Common Stock publicly traded?
Yes, Replimune Group, Inc. - Common Stock is publicly traded.
What exchange does Replimune Group, Inc. - Common Stock trade on?
Replimune Group, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Replimune Group, Inc. - Common Stock?
The ticker symbol for Replimune Group, Inc. - Common Stock is REPL on the Nasdaq Stock Market
What is the current price of Replimune Group, Inc. - Common Stock?
The current price of Replimune Group, Inc. - Common Stock is 10.84
When was Replimune Group, Inc. - Common Stock last traded?
The last trade of Replimune Group, Inc. - Common Stock was at 06/22/26 10:35 AM ET
What is the market capitalization of Replimune Group, Inc. - Common Stock?
The market capitalization of Replimune Group, Inc. - Common Stock is 506.78M
How many shares of Replimune Group, Inc. - Common Stock are outstanding?
Replimune Group, Inc. - Common Stock has 507M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.